Bayer to acquire KaNDy Therapeutics in $875M women’s health play August 11, 2020 Auto Bot Bayer, BioPharma, biopharma nl, Germany, U.K., womens health 0 KaNDy’s lead product candidate, NT-814, is a non-hormonal treatment for symptoms of menopause. The drug completed Phase IIb testing and is slated to start Phase III testing next year.